Drug intelligence / Profile preview

PUR-003

Development stage: Phase 1
Lead developer: Pulmatrix
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules
Administration: Inhalation

Overview

PUR-003 is an inhaled small molecule drug developed by Pulmatrix for respiratory and infectious diseases. It acts as an immunostimulant and was investigated primarily for the treatment of asthma and influenza. The compound is designed to stimulate the immune system in the airways, potentially reducing symptoms or severity of respiratory illnesses. Clinical trials have evaluated its safety and efficacy in both asthmatic patients and healthy adults challenged with influenza virus[2][1][3]. Its mechanism of action is broadly classified as immunostimulation; specific molecular targets have not been disclosed.

Beyond the preview

Go deeper on PUR-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PUR-003.

Explore the full profile